Articles not available on the internet can be purchased from the
LA Times.
Willman D. (1998)
Drugmaker
hires NIH researcher.
LA Times, 7 December
Willman D. (1998)
Sunday
Report; 'Fast-track' drug to treat diabetes tied to 33 deaths.
LA Times, 6 December
Willman D. (1998)
Waxman queries NIH on researcher's ties.
LA Times, 9 December.
Willman D. (1998)
NIH Director calls for review of scientist's ties to firm.
LA Times, 16 December 1998
Willman D. (1998).
Lawmakers
question FDA on Rezulin OK.
LA Times 23 December.
Willman D. (1999).
FDA orders reassessment of diabetes drug's safety.
LA Times, 16 January.
Willman D. (1999)
Researcher's
fees point to other potential conflicts at NIH.
LA Times, 28 January.
Willman D. (1999)
For recent victim, risk wasn't known.
LA Times, 18 March.
Willman D. (1999)
Death toll challenges rezulin safety claim.
LA Times, 18 March.
Willman D. (1999).
Rezulin's maker now says drug linked to as many as 35 deaths.
LA Times, 19 March.
Willman D. (1999).
2 new FDA panelists have ties to Rezulin maker.
LA Times, 25 March.
Willman D. (1999).
FDA advised to restrict Rezulin use for diabetes.
LA Times, 27 March.
Willman D. (1999).
FDA urged to heed warnings on Rezulin.
LA Times, 23 May.
Willman D. (1999).
2nd NIH researcher becomes a focus of conflict probe.
LA Times, 4 September.
Willman D. (1999).
Scientists who judged pill safety received fees.
LA Times, 29 October.
Willman D. (1999).
Deaths climb since FDA got Rezulin warning.
LA Times, 15 December.
Willman D. (2000).
Key
physician urges Rezulin be withdrawn.
LA Times, 19 February.
Willman D. (2000).
FDA, drug firm continue to debate worthiness of Rezulin.
LA Times, 29 February.
Willman D. (2000).
Fears grow over delay in removing Rezulin.
LA Times, 10 March.
Willman D. (2000).
FDA investigating Rezulin clinical trials.
LA Times, 15 March.
Willman D. (2000).
Physician who opposes rezulin is threatened by FDA with dismissal.
LA Times, 17 March.
Willman D. (2000).
Diabetes drug Rezulin pulled off the market.
LA Times, 22 March.
Willman D. (2000).
The rise and fall of the killer drug Rezulin. .
LA Times, 4 June
Willman D. (2000).
FDA's approval and delay in withdrawing Rezulin probed. (2000).
LA Times, 16 August.
Willman D. (2000).
FDA post-mortem finds drug approval problems.
LA Times, 16 November.
Willman D. (2000).
The new FDA. How a new policy led to seven deadly drugs.
LA Times,
20 December.
Willman D. (2000).
Rezulin: fast track approval and a slow withdrawal.
LA Times,
20 December.
Willman D. (2001).
Risk was known as FDA OKd fatal drug.
LA Times, 11 March, A1.
Willman D. (2002).
Hidden risks, lethal truths; Warner-Lambert won approval for Rezulin
after masking the scope of liver injuries in clinical studies.
LA Times, 30 June, A1.
Back to top
Other press material
Vedantam S. Diabetes drug pulled in Britain, called safe. U.S.
doctors say patients should not stop taking Rezulin as benefits
outweigh its effects on the liver. The Philadelphia Inquirer,
3 December 1997, p A02.
Back to top
CNN
FDA
panel recommends continued use of controversial diabetes drug,
26 March 1999
Back to top
CBS
Drug
maker wants rezulin review. CBS News, 20 July 2000.
Back to top
Doctor's Guide Publishing
Troglitazone
chosen for first major diabetes prevention study. Press release.
Doctor's Guide Publishing, 11 June 1996.
Rezulin
for type II Diabetes cleared by FDA. Press release. Doctor's
Guide Publishing, 30 January 1997.
NIH
tests rezulin as part of prevention study. Press release.
Doctor's Guide Publishing, 30 January 1997.
Warner-Lambert
pleased by FDA Advisory Committee recommendation on Rezulin.
Press release. Doctor's Guide Publishing, 29 March 1999.
FDA
panel says rezulin should stay on market. Press release. Doctor's
Guide Publishing, 29 March 1999
FDA,
Parke-Davis urge limits on rezulin use. Press release. Doctor's
Guide Publishing, 17 June 1999.
Back to top
Back to resources page
